Comprehensive Genomic Profiling PLUS
The Caris Molecular Intelligence CGP+ approach to tumour profiling assesses DNA, RNA and proteins to reveal a more complete molecular blueprint to guide precise and individualised treatment decisions that are proven to extend overall survival.
Understanding the molecular phenotypes of cancer to personalise therapy requires more than DNA sequencing.
CGP+ Profiling Technologies
Caris Molecular Intelligence uses multiple tumour profiling technologies to decode cancer and better understand the biology driving tumour growth.
- Next-Generation Sequencing (NGS) for DNA and RNA: Rapidly examines and more broadly detects mutations, copy number variations, gene fusions and variant transcripts across the genome
- Pyro Sequencing (PyroSeq): Detects and quantifies mutations, methylation, etc. through sequencing by synthesis
- Fragment Analysis (FA/Frag. Analysis): Detects changes in DNA or RNA to indicate the presence or absence of a genetic marker; useful in limited tissue situations, i.e. lung cancer
- Polymerase Chain Reaction (PCR): Quickly amplifies copies of a specific region of DNA or RNA for analysis
- Immunohistochemistry (IHC): Determines level of protein expression
- in situ Hybridization: Detects gene deletions, amplifications, translocations and fusions
- Microdissection: Tumour enrichment to increase and isolate a larger portion of cancer cells and improve the chances for successful testing from small tumour samples
MI Profile Report
Caris Molecular Intelligence reports are built to maximise clinical utility in an easy-to-interpret format. We understand that clinicians need treatment information fast. That’s why our report was built by oncologists for oncologists. With results back in under 3 weeks, we’ll help you find answers when you need them the most.
Immunotherapy Diagnostics Expertise
By harnessing the body’s immune system to detect and destroy tumour cells, immune checkpoint inhibitors are rapidly ushering in a new era of precision medicine. Identify patients more likely to respond to immunotherapies with reliable molecular information based on validated assays for PD-L1, MSI and TMB testing in our state-of-the-art laboratory.
Programmed death ligand-1 (PD-L1) is among the most important checkpoint proteins that mediate tumour-induced immune suppression through T-cell downregulation. PD-L1 expression may indicate a more likely response to immunotherapies.
Experience data across all lineages: 64,000+
MSI (Next-Generation Sequencing)
Microsatellite instability is caused by failure of the DNA mismatch repair (MMR) system. MSI-High correlates to an increased neoantigen burden, which makes the tumour more likely to respond favourably to immunotherapies.
Experience data across all lineages: 24,000+
TMB (Next-Generation Sequencing)
Total mutational burden (TMB) measures the total number of non-synonymous somatic mutations identified per megabase of the genome coding area. Tumours with high TMB likely harbour neoantigens and may respond more favourably to immunotherapies.
Experience data across all lineages: 33,000+
Treatment Decisions Informed with Tumour Profiling Improve Clinical Outcomes
As the foremost tumour profiling service, Caris Molecular Intelligence helps oncologists illuminate better treatment plans proven to extend overall survival and improve clinical outcomes.
Matching molecular phenotypes for treatment selection leads to improved clinical outcomes.
- Patients who received only those treatments associated with potential benefit according to the CMI report (n=534), had a significantly longer post-profiling survival compared to those in the Unmatched cohort (n=493). The median increase in survival was 422 days (1068 vs. 646 days, Hazard Ratio = 0.68, p=0.001).
- Patients in the Matched cohort were treated with fewer treatments overall after profiling compared to those in the Unmatched cohort (median 3.2 vs. 4.2 therapies).
With the promise of precision medicine becoming a reality, molecular profiling has become standard of care for many cancer types – and required for certain therapies (Companion Dx). More than ever, oncologists need a trusted tumour profiling partner to provide reliable, high-quality molecular information to guide more precise and individualised treatment decisions.
Caris Molecular Intelligence® identifies key molecular features of cancer and provides molecular insights to aid oncologists in personalising cancer therapies for their patients. Caris Molecular Intelligence helps oncologists:
- Navigate among therapies with potential benefit;
- Identify therapies that may not have been considered;
- Determine drugs with potential lack of benefit (avoiding unnecessary toxicities and costs); and
- Match patients to clinical trials.
The Largest and Most Experienced Tumour Profiling Service
- Unmatched experience:
- ~1,900,000 tests completed;
- ~120,000 clinical cases performed;
- Improved clinical outcomes:
- 422 day increase in median overall survival;
- One less therapy utilised;
- Immunotherapy Dx expertise:
- Microsatellite Instability (MSI);
- Total Mutational Burden (TMB);
- Rigorous quality standards:
- CAP, CLIA, NYSDOH, ISO15189, CE Mark certified/approved;
- 66,000-square-foot central laboratory;
- Staffed by: bioinformaticians, oncologists, molecular geneticists, pathologists and PhD scientists;
- Limited tissue capabilities:
- Multiple reflex options to alternative technologies/methods;
- Tumour enrichment via microdissection;
- Rapid turnaround time:
- Report in under 3 weeks from ordering to results.